Abstract
Various drugs have been developed and trialed for boron neutron capture therapy (BNCT) but p-borono-phenylalanine (BPA) is one of the most successful compounds to date. BPA was originally developed as a selective targeting drug for BNCT of brain tumours on the basis that cancer cells require increased quantities of amino acids in order to maintain their faster metabolism compared to normal cells.1 Melanoma cells actively transport and metabolise aromatic amino acids such as phenylalanine and tyrosine for use as precursors in the synthesis of the pigment, melanin. BPA, being a phenylalanine derivative, is believed to exploit this mechanism resulting in the selective uptake in melanoma tumours and the successful application of BNCT in animals and some human patients.2–5
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Snyder FIR, Reedy AJ, Lennarz W. Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine, J. Am. Chem. Soc. 80: 835–838, 1958.
Mishima Y, Honda O, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino K. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma seeking B-10 compound, Lancet 1989 ii: 388–389.
Allen Bi, Corderoy-Buck S, Mallesch JL, Crotty K, Moore DE. Local control of subcutaneous melanoma xenografts in nude mice by neutron capture therapy, Melanoma Res. 2: 253–262, 1992.
Coderre JA, Glass JD, Fairchild RG, Roy U, Cohen S, Fand I. Selective targeting ofboronophenylalanine to melanoma in Balb/c mice for neutron capture therapy, Cancer Res. 47: 6377–6383, 1987.
Mallesch JL, Moore DE, Allen BJ, McCarthy WH, Jones R, Stening W. The pharmacokinetics of p-boronophenylalanine.fructose in human patients with glioma and metastatic melanoma. Int. J. Rad. One. Biol. Phys. 28: 1183–1188, 1994.
Albert A, “Selective Toxicity” 7th Ed. Chapman AND Hall, London, 1985, pp. 490–500.
Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumours other than melanoma, Cancer Res. 50: 138–141, 1990.
Ichihashi M, Fukuda H, Brown JK, Mountford MH, Allen BJ, Wilson JG, Mishima Y. In-vitro evaluation of 1°B-BPA for melanoma at Moata–Joint work between Japan and Australia BNCT research teams, in: “Progress in Neutron Capture Therapy for Cancer,” BJ Allen, DE Moore, BY Harrington, eds. Plenum Press, New York, 1992, pp. 387–390.
Coderre JA, Packer S, Greenberg D, Micca PL, Joel DD, Saraf S. Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine, in: “Progress in Neutron Capture Therapy for Cancer,” BJ Allen, DE Moore, BV Harrington, eds. Plenum Press, New York, 1992, pp. 463–468.
Coderre JA. A phase-1 biodistribution study of p-boronophenylalanine, in: “Boron Neutron Capture Therapy,” D Gabel, R Moss, eds. Plenum Press, New York, 1992, pp. I I I - 121.
Mori, Y, Susuki K, Yoshino K, Kakihana H. Complex formation of p-boronophenylalanine with some monosaccharides. Pigment Cell Res. 2: 273–277, 1989.
Tamat SR, Moore DE, Allen BJ. Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry. Anal. Chem. 59: 2161–2164, 1987.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moore, D.E., Mallesch, J.L., McCarthy, W.H., Allen, B.J. (1996). Pharmacokinetic Comparison Between L & D, L-BPA. Fructose in a Murine Melanoma Model and in Human Patients with Metastatic Melanoma. In: Mishima, Y. (eds) Cancer Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9567-7_98
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9567-7_98
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9569-1
Online ISBN: 978-1-4757-9567-7
eBook Packages: Springer Book Archive